Genomic change | Previous reports | Current study | |||||||
---|---|---|---|---|---|---|---|---|---|
 | Reference | Region | % Tumors | Cytobanda | Start (Mb)a,b | Stop (Mb)a,b | Size (Mb)a,b | % Tumors | Cancer genes |
Gains | Â | Â | Â | Â | Â | Â | Â | Â | Â |
1q+ | Â | Â | Â | 1p36.32 | 2.0 | 6.0 | 4.0 | 49 | Â |
1q+ | Â | Â | Â | 1q23.3 | 158.8 | 159.6 | 0.8 | 57 | Â |
1q+ | [5-10] | 1q32 | 48–67 | 1q32.1 | 202.1 | 202.9 | 0.8 | 66 |  |
1q+ | Â | Â | Â | 1q42.12-42.13 | 221.8 | 225.9 | 4.1 | 53 | Â |
4p+ | Â | Â | Â | 4p16.1 | 7.1 | 8.8 | 1.7 | 51 | Â |
5p+ | [6] | 5p12-14 | 24 | 5p15.33 | 0 | 1.9 | 1.9 | 49 | TERT |
8q+ | [5-10] | 8q22-qter | 39–49 | 8q24.3 | 139.3 | 144.8 | 5.6 | 79 | PTK2 |
9q+ | Â | Â | Â | 9q34.13-34.3 | 130.5 | 135.2 | 4.6 | 53 | TSC1 RALGDS |
16p+ | [6] | 16p | 38–40 | 16p13.3 | 3.2 | 3.3 | 0.1 | 57 | MMP25 |
17q+ | [6-10] | 17q12 | 18–60 | 17q12 | 33.6 | 38.9 | 5.3 | 45 | TAF15 MLLT6 ERBB2 |
17q+ | [5-10] | 17q22-25 | 18–60 | 17q25.3 | 77.7 | 81.1 | 3.5 | 45 | GRB2 TIMP2 |
20q+ | [5-10] | 20q13 | 18–44 | 20q13.12 | 43.8 | 45.7 | 1.9 | 49 | MMP9 |
Losses | Â | Â | Â | Â | Â | Â | Â | Â | Â |
4q- | Â | Â | Â | 4q31.1-31.21 | 141.6 | 145.2 | 3.6 | 40 | Â |
4q- | Â | Â | Â | 4q32 | 156.1 | 160.1 | 4.0 | 36 | Â |
4q- | Â | Â | Â | 4q32.2 | 162.9 | 164.2 | 1.3 | 32 | Â |
8p- | [7] | 8p22-23 | 20 | 8p23.1-23.2 | 4.8 | 7.6 | 2.8 | 40 | Â |
8p- | [6,8,10] | 8p | 18–29 | 8p21.3 | 19.9 | 20.0 | 0.1 | 32 |  |
 |  |  |  | 8p21.2 | 23.5 | 27.5 | 4.0 | 36 | PTK2B |
 |  |  |  | 8p12 | 34.8 | 35.6 | 0.8 | 32 |  |
9p- | [6,7,9] | 9p22-24 | 20–23 | 9p21.2 | 27.6 | 27.9 | 0.3 | 30 |  |
13q- | [6-8,10] | 13q21-31; 13q22-31 | 18–57 | 13q14.13 | 44.6 | 45.1 | 0.5 | 30 | LCP1 |
16q- | [6-8] | 16q21-qter; 16q23-24 | 20–38 | 16q21 | 61.5 | 63.5 | 2.0 | 34 | CDH8 |
17p- | Â | Â | Â | 17p12 | 11.5 | 11.6 | 0.1 | 32 | Â |
18p- | Â | Â | Â | 18p11.31-11.23 | 6.1 | 7.6 | 1.5 | 36 | Â |
21q- | Â | Â | Â | 21q11.2-21.1 | 15.3 | 15.9 | 0.6 | 32 | Â |